Lenvatinib: tested on its own
79 studies: no other medicine in its arm. Page 1 of 1. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.
- Lenvatinib in Patients With Advanced Parathyroid CarcinomaNot yet recruitingNCT07843901Phase 2Report a problem
- Lenvatinib Plus Chemotherapy for pNET Liver MetastasesRecruitingNCT07835893Phase 2Report a problem
- PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCCNot yet recruitingNCT07827807Phase 2Report a problem
- Clinical Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients With Advanced Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and FluoropyrimidineEnrolling by invitationNCT07683949Phase 1/2Report a problem
- First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative TreatmentRecruitingNCT07297654Phase 2Report a problem
- Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant AscitesRecruitingNCT07149090Phase 1/2Report a problem
- Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST PatientsRecruitingNCT07096609Phase 1/2Report a problem
- Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)RecruitingNCT07092514Phase 2Report a problem
- Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical StudyRecruitingNCT06794073Not applicableReport a problem
- Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After SurgeryRecruitingNCT06762782Phase 2Report a problem
- Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic CholangiocarcinomaNot yet recruitingNCT06417606Phase 4Report a problem
- Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular CarcinomaRecruitingNCT06327269Early Phase 1Report a problem
- Lenvatinib for Advanced Bone and Soft Tissue SarcomaRecruitingNCT05617859Phase 2Report a problem
- Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular CarcinomaRecruitingNCT05444478Not applicableReport a problem
- Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)RecruitingNCT04858867Not applicableReport a problem
- Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor ThrombusNot yet recruitingNCT04319484Phase 2/3Report a problem
- A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)CompletedNCT04447755Phase 2Results postedReport a problem
- Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid CancerTerminatedNCT03506048Phase 2Results postedReport a problem
- Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)TerminatedNCT03433703Phase 2Results postedReport a problem
- Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by SurgeryCompletedNCT03008369Phase 2Results postedReport a problem
- Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy VolunteersCompletedNCT02792829Phase 1Results postedReport a problem
- Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy VolunteersCompletedNCT02723630Phase 1Results postedReport a problem
- A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety ProfileCompletedNCT02702388Phase 2Results postedReport a problem
- Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid TumorsCompletedNCT02686164Phase 1Results postedReport a problem
- Lenvatinib Efficacy in Metastatic Neuroendocrine TumorsCompletedNCT02678780Phase 2Results postedReport a problem
- A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)TerminatedNCT02657369Phase 2Results postedReport a problem
- Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination ChemotherapyCompletedNCT02579616Phase 2Results postedReport a problem
- A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.CompletedNCT02578316Phase 1Results postedReport a problem
- Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the LungCompletedNCT01877083Phase 2Results postedReport a problem
- A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular CarcinomaCompletedNCT01761266Phase 3Results postedReport a problem
- A Study of E7080 in Subjects With Advanced Thyroid CancerCompletedNCT01728623Phase 2Results postedReport a problem
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)CompletedNCT01321554Phase 3Results postedReport a problem
- A Study of E7080 in Subjects With Solid TumorCompletedNCT01268293Phase 1Results postedReport a problem
- An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV MelanomaCompletedNCT01136967Phase 2Results postedReport a problem
- Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease ProgressionCompletedNCT01111461Phase 2Results postedReport a problem
- Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)CompletedNCT00946153Phase 1/2Results postedReport a problem
- Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by HistologyCompletedNCT00784303Phase 2Results postedReport a problem
- An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid TumorsCompletedNCT00280397Phase 1Results postedReport a problem
- An Open Label Dose Escalation Study Of E7080CompletedNCT00121719Phase 1Results postedReport a problem
- Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular CarcinomaActive, not recruitingNCT06138769Phase 2Report a problem
- Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular CarcinomaActive, not recruitingNCT05901194Phase 1/2Report a problem
- Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular CarcinomaStatus unknownNCT05391867Not applicableReport a problem
- Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer PatientsStatus unknownNCT05221775Phase 1Report a problem
- TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver CancerStatus unknownNCT05220020Phase 3Report a problem
- Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma PatientsCompletedNCT05171335Phase 2Report a problem
- Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous AblativeActive, not recruitingNCT05113186Phase 2Report a problem
- Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver TransplantTerminatedNCT05103904Phase 2Report a problem
- Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular CarcinomaStatus unknownNCT04961138Not applicableReport a problem
- Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCCStatus unknownNCT04911959Phase 1/2Report a problem
- Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCCCompletedNCT04791176Phase 2Report a problem
- Lenvatinib in Patients With Previously Treated Advanced Biliary Tract CancerCompletedNCT04656249Phase 2Report a problem
- TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 TrialStatus unknownNCT04531228Not applicableReport a problem
- TACE Combined With Lenvatinib for Unresectable Hepatocellular CarcinomaStatus unknownNCT04490694Phase 2Report a problem
- Lenvatinib in Locally Advanced Invasive Thyroid CancerCompletedNCT04321954Phase 2Report a problem
- A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCCCompletedNCT04297254Phase 4Report a problem
- Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCCStatus unknownNCT04241523Phase 2Report a problem
- Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular CarcinomaStatus unknownNCT04227808Phase 2Report a problem
- Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib FailureCompletedNCT04193553Phase 2Report a problem
- Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTTStatus unknownNCT04127396Phase 4Report a problem
- The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.Status unknownNCT04053972Phase 3Report a problem
- Lenvatinib for Unresectable Intrahepatic CholangiocarcinomaWithdrawnNCT03801499Phase 2Report a problem
- HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCCStatus unknownNCT03775395Phase 3Report a problem
- A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid CancerCompletedNCT03573960Phase 4Report a problem
- Phase II Study of Single Agent LenvatinibStatus unknownNCT03168074Phase 2Report a problem
- Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid TumorCompletedNCT03009292Phase 1Report a problem
- Lenvatinib in Second Line Endometrial CarcinomaWithdrawnNCT03005015Phase 2Report a problem
- A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in ChinaCompletedNCT02966093Phase 3Report a problem
- Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT02953743Phase 1Report a problem
- Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14CompletedNCT02860936Phase 2Report a problem
- Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR SignalingWithdrawnNCT02846766Phase 2Report a problem
- Testing Lenvatinib in Patients With Adenoid Cystic CarcinomaActive, not recruitingNCT02780310Phase 2Report a problem
- Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid CancerCompletedNCT02726503Phase 2Report a problem
- A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)CompletedNCT02421042Phase 1Report a problem
- A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy VolunteersCompletedNCT02199392Phase 1Report a problem
- A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy SubjectsCompletedNCT02199379Phase 1Report a problem
- A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy VolunteersCompletedNCT02198170Phase 1Report a problem
- A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc IntervalCompletedNCT01525394Phase 1Report a problem
- E7080 Food Effect Study in Healthy SubjectsCompletedNCT01240408Phase 1Report a problem
- A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic MelanomaCompletedNCT00121680Phase 1Report a problem